Trial · NCT00371254
Results by group132
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 132
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Complete Response (CR) or Partial Response (PR) | Dasatinib 100 mg BID | 2 | participants | ||
| Number of Participants With Complete Response (CR) or Partial Response (PR) | Dasatinib 70 mg BID | 0 | participants | ||
| Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at or After 16 Weeks on Study | Dasatinib 100 mg BID | 3 | Participants | ||
| Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at or After 16 Weeks on Study | Dasatinib 70 mg BID | 1 | Participants | ||
| Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at or After 16 Weeks on Study | Dasatinib 100 mg BID | 13.04 | 95% Confidence Interval 2.78 to 33.59 | percentage of participants | |
| Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) at or After 16 Weeks on Study | Dasatinib 70 mg BID | 5.0 | 95% Confidence Interval 0.13 to 24.87 | percentage of participants | |
| Proportion of Participants With Progression-Free Survival (PFS) at Weeks 9, 17, and 25 | Dasatinib 100 mg BID | Week 9 | 0.40 | 0.13 | Proportion of Participants |
| Proportion of Participants With Progression-Free Survival (PFS) at Weeks 9, 17, and 25 | Dasatinib 70 mg BID | Week 9 | 0.35 | 0.12 | Proportion of Participants |
| Proportion of Participants With Progression-Free Survival (PFS) at Weeks 9, 17, and 25 | Dasatinib 100 mg BID | Week 17 | 0.32 | 0.13 | Proportion of Participants |
| Proportion of Participants With Progression-Free Survival (PFS) at Weeks 9, 17, and 25 | Dasatinib 70 mg BID | Week 17 | 0.14 | 0.09 | Proportion of Participants |
| Proportion of Participants With Progression-Free Survival (PFS) at Weeks 9, 17, and 25 | Dasatinib 100 mg BID | Week 25 | 0.21 | 0.12 | Proportion of Participants |
| Proportion of Participants With Progression-Free Survival (PFS) at Weeks 9, 17, and 25 | Dasatinib 70 mg BID | Week 25 | 0.00 | 0.00 | Proportion of Participants |
| Mean Number of Weeks of Complete Response (CR) or Partial Response (PR) | Dasatinib 100 mg BID | 31 | Full Range 8.14 to 53.86 | weeks | |
| Mean Plasma Concentration at Week 3 | Dasatinib 100 mg BID | 0 hour (n = 10, 10, 1) | 9.02 | Standard Deviation 3.79 | nanograms (ng)/mL |
| Mean Plasma Concentration at Week 3 | Dasatinib 70 mg BID | 0 hour (n = 10, 10, 1) | 7.14 | Standard Deviation 4.41 | nanograms (ng)/mL |
| Mean Plasma Concentration at Week 3 | Dasatinib 50 mg BID | 0 hour (n = 10, 10, 1) | 2.88 | Standard Deviation NA | nanograms (ng)/mL |
| Mean Plasma Concentration at Week 3 | Dasatinib 100 mg BID | 1 hour (n = 10, 10, 1) | 103.35 | Standard Deviation 80.94 | nanograms (ng)/mL |
| Mean Plasma Concentration at Week 3 | Dasatinib 70 mg BID | 1 hour (n = 10, 10, 1) | 66.41 | Standard Deviation 47.53 | nanograms (ng)/mL |
| Mean Plasma Concentration at Week 3 | Dasatinib 50 mg BID | 1 hour (n = 10, 10, 1) | 35.05 | Standard Deviation NA | nanograms (ng)/mL |
| Mean Plasma Concentration at Week 3 | Dasatinib 100 mg BID | 3 hour (n = 10, 10, 1) | 50.98 | Standard Deviation 35.23 | nanograms (ng)/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00371254/results